Moderna, Inc.

How big is Moderna, Inc.?

As of Jun 18, Moderna, Inc. has a market capitalization of $9.88 billion, with recent net sales of $3.18 billion and a net profit of -$3.36 billion. Shareholder's funds are $10.90 billion, and total assets are $14.14 billion.

Market Cap: As of Jun 18, Moderna, Inc. has a market capitalization of 9,881.25 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Moderna reported net sales of 3,177.00 million and a net profit of -3,357.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the shareholder's funds amounted to 10,901.00 million, while total assets were reported at 14,142.00 million.

What does Moderna, Inc. do?

Moderna, Inc. is a large-cap biotechnology company focused on transformative medicines using mRNA technology. As of March 2025, it reported net sales of $108 million and a net loss of $971 million, with a market cap of approximately $9.88 billion.

Overview: <BR>Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA) and operates within the Pharmaceuticals & Biotechnology industry, classified as a large-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 108 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -971 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 9,881.25 Million (Large Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.59 <BR>Return on Equity: -33.35% <BR>Price to Book: 0.98<BR><BR>Contact Details: <BR>Address: 200 Technology Sq, Cambridge MA: 02139-3578 <BR>Tel: 1 617 7146500 <BR>Fax: 1 617 5831998 <BR>Website: https://www.modernatx.com/

Should I buy, sell or hold Moderna, Inc.?

Who are in the management team of Moderna, Inc.?

As of March 2022, the management team of Moderna, Inc. includes Dr. Noubar Afeyan (Chairman), Mr. Stephane Bancel (CEO), and several independent directors, including Ms. Elizabeth Tallett and Dr. Robert Langer, among others. They are responsible for guiding the company's strategic direction and operations.

As of March 2022, the management team of Moderna, Inc. includes the following individuals:<BR><BR>- Dr. Noubar Afeyan: Non-Executive Independent Chairman of the Board, Co-Founder<BR>- Mr. Stephane Bancel: Chief Executive Officer, Director<BR>- Ms. Elizabeth Tallett: Director<BR>- Mr. Stephen Berenson: Non-Executive Independent Director<BR>- Dr. Robert Langer: Non-Executive Independent Director<BR>- Mr. Francois Nader: Non-Executive Independent Director<BR>- Mr. Israel Ruiz: Non-Executive Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Is Moderna, Inc. overvalued or undervalued?

As of November 2, 2023, Moderna, Inc. is considered overvalued with a risky valuation grade, reflected by key metrics such as a Price to Book Value of 1.05 and a -90.22% ROCE, alongside a year-to-date stock performance of -38.79%, significantly underperforming the S&P 500's 12.22% return.

As of 2 November 2023, the valuation grade for Moderna, Inc. has moved from expensive to risky, indicating a significant deterioration in its financial outlook. Based on the available metrics, the company appears to be overvalued. Key ratios include a Price to Book Value of 1.05, an EV to Sales ratio of 1.48, and a troubling ROCE of -90.22%. In comparison, Illumina, Inc. has a fair valuation with a P/E of 19.09, while BioMarin Pharmaceutical, Inc. also maintains a fair valuation with a P/E of 15.17.<BR><BR>Moderna's stock has underperformed significantly against the S&P 500, with a year-to-date return of -38.79% compared to the S&P 500's 12.22%. This stark contrast further supports the conclusion that the stock is overvalued in the current market environment.

Is Moderna, Inc. technically bullish or bearish?

As of October 31, 2025, Moderna, Inc. is in a mildly bearish trend, with mixed technical indicators showing some bullish signals but overall underperformance compared to the S&P 500, including a year-to-date return of -42.88%.

As of 31 October 2025, the technical trend for Moderna, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows a bullish signal on the monthly but no signal on the weekly. However, the Bollinger Bands, KST, and moving averages indicate bearish trends, particularly on the daily and weekly time frames. Dow Theory shows no trend in both weekly and monthly evaluations.<BR><BR>In terms of performance, Moderna has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -42.88% compared to the S&P 500's 16.30%, and a one-year return of -56.53% versus 19.89% for the index.